NCT03080051View on ClinicalTrials.gov

Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

March 6, 2017

Study Completion Date

March 6, 2017

Conditions
Progressive Supranuclear PalsyAlzheimer DiseaseHealthy Volunteers
Interventions
DRUG

[18F]MNI-952

Subjects will undergo PET imaging using \[18F\]MNI-952, a PET radioligand for imaging tau.

DRUG

[18F]Florbetapir

Subjects with Alzheimer's disease will receive a \[18F\]florbetapir scan to compare distribution of tau in the brain compared to that of \[18F\]MNI-952.

Trial Locations (1)

06510

Molecular NeuroImaging, LLC, New Haven

Sponsors
All Listed Sponsors
lead

Molecular NeuroImaging

OTHER